If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown.
T he recognition that overexpression of immune checkpoint molecules in the tumor microenvironment plays a crucial role in antitumor immunity evasion has revolutionized cancer therapy. [1] [2] [3] Currently, 6 immune checkpoint inhibitors (ICI) have been approved for the treatment of different advanced solid tumors: the CTLA-4 (cytotoxic Tlymphocyte-associated protein 4) inhibitor ipilimumab; 2 PD-1 (programmed cell death protein 1) inhibitors, nivolumab and pembrolizumab; and 3 PD-L1 (programmed cell death 1 ligand 1) inhibitors, atezolizumab, avelumab, and durvalumab. Additionally, combination therapy of ipilimumab plus nivolumab has been approved for treatment of advanced melanoma. Given the still-growing list of cancer types in which ICI have demonstrated clinical activity, their use is expected to increase in the coming years. 4 Immune checkpoint molecules have an important function in regulating immune response: after binding to their ligands, these proteins can initiate either inhibitory or stimulatory pathways that modulate T-cell function.
2 Both
CTLA-4 and PD-1 play a key role in the maintenance of immunological tolerance to self-antigens, preventing autoimmune disorders. [5] [6] [7] [8] Therefore, at the same time that ICI are able to unleash T cells to fight cancer, they also can trigger autoimmunelike manifestations in different organ systems, generally referred to as immune-related adverse events (irAEs). Endocrine dysfunctions are among the most common irAEs that have been reported in clinical trials with ICI, including hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency (PAI), and insulin-deficient diabetes (IDD). 9, 10 However, there has been no report of a systematic review or meta-analysis of the incidence of these dysfunctions across different US Federal Drug Administration (FDA)-approved ICI regimens, or across different tumor subtypes.
Given the increasing use of these agents in clinical practice, and the life-threatening nature of endocrine dysfunction if not promptly recognized, we performed a systematic review and meta-analysis of clinical trials with FDAapproved ICI regimens in patients with advanced solid tumors and compared the incidence and risks of endocrine irAEs associated with each regimen.
Methods

Search Methods and Study Selection
We conducted a systematic search of the literature to identify clinical trials of ICI that reported endocrine adverse events (AEs). Original articles that have published results of prospective clinical trials of these ICI regimens for patients with advanced solid tumors, including monotherapy and combination therapy trials, were identified by a PubMed search, and by examining the references of published trials, review articles, editorials, and other relevant articles. The latest manufacturer package inserts were also retrieved. For the PubMed search, the following keywords or corresponding Medical Subject Heading terms were used: "ipilimumab," "MDX-010," "nivolumab," "BMS-963558," "pembrolizumab," "MK-3475," "atezolizumab," "MPDL3280A," and "phase." Articles published online ahead of print were included. The database was searched for articles published on or before July 18, 2016 . The search focused on the trials of these 4 agents because at that time, those were the only drugs approved by the FDA.
Our selection criteria included all prospective clinical trials (and/or cohorts) that: (1) investigated the usage of the previously mentioned ICI for treatment of advanced solid tumors; (2) clearly reported an endocrine AE in their safety data, with or without clinical severity grading; and (3) were published in the English language. We excluded trials that: (1) involved combination regimens with other therapies and/or modalities other than ICI (eg, targeted therapy, chemotherapy, radiation therapy, other immunotherapy); (2) did not list endocrine AEs in any arm and/or cohort; and (3) were presented only as meeting abstracts without published full-text original articles. One exception was made for atezolizumab. Given that this agent was recently approved, and there are few clinical trials available, we used unpublished data on phase 1 clinical trial (NCT01375842) that was provided to us by the study sponsor (Genentech Inc). In the event of duplicates, ambiguity, or publications reporting on the same study population, only the most recent, relevant, and/or comprehensive publication was included in the analysis. Any discrepancy in study selection was resolved by consensus.
Data Extraction
The total number of patients treated with ICI, and the number of patients with endocrine dysfunction (hypothyroidism, hyperthyroidism, hypophysitis, PAI, and IDD) for all grades and for grade 3 and higher were collected from the eligible articles. Toxic effects listed as thyroiditis were excluded for 2 reasons: (1) most trials did not report this event and (2) the possible overlapping between its occurrence and both hypothyroidism and hyperthyroidism. The trial phases, tumor types, types of specific agents (ipilimumab, nivolumab, pembrolizumab, or atezolizumab), doses, and frequency of drug administration were recorded. The treatment regimen was classified as CTLA-4 inhibitor, PD-1 inhibitor, or PD-L1 inhibitor when these agents were administered as monotherapy, or as
Key Points
Question What is the incidence and what are the risks of endocrine dysfunction related to different immune checkpoint inhibitor regimens in patients with advanced solid tumors?
Findings In this meta-analysis of 38 clinical trials including 7551 patients, the incidence of endocrine dysfunction was significantly higher in those treated with combination therapy compared with ipilimumab. Regarding monotherapy, the incidence of thyroid dysfunction and hypophysitis was highest with programmed cell death protein 1 inhibitors and with ipilimumab, respectively.
Meaning Our study provides more precise data on the incidence of endocrine dysfunctions among patients receiving immune checkpoint inhibitor regimens; such events were higher in patients treated with combination therapy.
combination therapy when was ipilimumab plus nivolumab was given in a concurrent regimen. The data extraction was performed by 1 primary reviewer (R.B.-S.) and was then independently reviewed by 2 secondary reviewers (W.T.B. and A.C.G.-C.) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Statistical Analysis
For each clinical trial, the number of patients treated and the number of patients with AEs reported was recorded for each treatment arm and dose level. The observed incidence of each toxic effect is reported by arm with 95% exact confidence intervals. Meta-analysis was performed using random effects models weighted by the number of patients treated.
11
All models were fit using log-odds transformation and restricted maximum likelihood estimation using an offset of 0.5 for all 0 cells. Heterogeneity was evaluated using the Cochran Q statistic and I 2 statistics for its proportion of the total variability. Predictors of AEs were explored in multivariable models, using likelihood ratio tests under maximumlikelihood and a 2-sided P value cutoff of .05 was considered statistically significant.
Step-down tests contrasting the incidence between monotherapy regimen applied a Bonferroni correction for the 3 pairwise relationships. Sensitivity analyses considered offsets of 0.5 in all and in no cells, fixedeffects models, and models using raw proportions. Results from sensitivity analyses are consistent unless otherwise noted. All analyses were performed using R 3.1.1 12 (R Project) and the metafor package. 13 
Results
Eligible Studies and Characteristics
The PubMed search and the review of reference lists identified a total of 683 records ( Figure 1) . After screening and eligibility assessment, we identified a total of 38 clinical trials that are represented in the data set (eTable 1 in the Supplement). This includes 8 phase 3 studies; 1, phase 2/3; 14, phase 2; 2, phase 1/2; and 13, phase 1. Within these studies, the following cohorts were excluded from analysis: 7 cohorts treated with chemotherapy alone, 1 cohort that included everolimus, and 3 cohorts with included vaccines. This left a total of 71 cohorts of patients to evaluate the incidence of endocrine AEs with ICI. The number of patients per cohort with safety data ranged from 3 to 558 (median, 54 patients), with a total of 7551 patients with AE data among the 7657 total enrolled across studies (98.6%). The most common disease types were melanoma (25 cohorts; n = 3346 patients), non-small-cell lung cancer (10 cohorts; n = 1906 patients), and renal cell carcinoma (6 cohorts; n = 664 patients).
We categorized the regimens by class as monotherapy with a PD-1 inhibitor (48 cohorts; n = 4953 patients), a CTLA-4 inhibitor (12 cohorts; n = 1013 patients), a PD-L1 inhibitor (3 cohorts; n = 1010 patients), and combination therapy with PD-1 (nivolumab) plus CTLA-4 inhibitor (ipilimumab) (8 cohorts; n = 575 patients). Specific PD-1 inhibitors include nivolumab (26 cohorts; n = 2494 patients) and pembrolizumab (22 cohorts; n = 2459 patients). All cohorts of CTLA-4 inhibitor and PD-L1 inhibitor included, respectively, ipilimumab and atezolizumab.
Dose information was abstracted for each cohort; for ipilimumab, pembrolizumab, and nivolumab, we used a threshold of 10 mg/kg to indicate high vs low dose. Only 1 cohort received high-dose ipilimumab, and only 3 cohorts received high-dose nivolumab, preventing us from making crossstudy comparisons. With pembrolizumab, 13 of 22 cohorts received a high dose (n = 1804 patients); and 9 cohorts received a low dose (n = 655 patients); a dose effect was explored with this agent (eTable 1 in the Supplement).
Incidence of Hypothyroidism
Across all study arms, 472 cases of any-grade hypothyroidism were observed among the 7551 patients enrolled in 38 studies (eTable 1 in the Supplement). One study did not report events by grade, but across other studies only 9 cases of grade 3 or higher hypothyroidism were reported (0.12% of patients).
Using the mixed-effects model, the overall incidence of hypothyroidism was estimated to be 6.6% (95% CI, 5.5%-7.8%), and a statistically significant difference was observed among the classes of ICI regimens (P < .001) (Figure 2 ).
14-50 The predicted incidence of hypothyroidism ranged from 3.8% (95% Herbst et al, 20 2015 Ribas et al, 23 2015 Patnaik et al, 26 2015 Garon et al, 24 2015 Robert et al, 18 2015 Robert et al, 32 2014 Gettinger et al, 29 2016 Antonia et al, 35 2016 Weber et al, 21 2016 Borghaei et al, 27 2015 Motzer et al, 22 2015 Hamanishi et al, 16 2015 Brahmer et al, 33 2015 Larkin et al, 19 2015 Weber et al, 30 2015 Rivzi et al, 37 2015 Motzer et al, 28 2015 Robert et al, 31 2015 Wolchok et al, 36 2013 Topalian et al, 39 2012 Nanda et al, 34 2016 Brahmer et al, 38 2010 Fehrenbacher et al, 14 2016 Rosenberg et al, 15 difference in risk of hypothyroidism between PD-1 and PD-L1 inhibitors did not reach statistical significance (OR, 0.53; 95% CI, 0.29-0.96; adjusted P = .11). The odds of experiencing hypothyroidism were not significantly different between patients treated with the PD-L1 inhibitor and ipilimumab. The test of residual heterogeneity among studies was highly significant (Q =98,P = .01, I 2 = 33.9%) (eFigure 1 in the Supplement); however, no other study-level factors were identified to be associated with hypothyroidism. In addition, no substantial difference in rates of hypothyroidism was observed among PD-1 inhibitors (nivolumab, 6.5% vs pembrolizumab, 7.9%) or in dose of pembrolizumab (7.6% with <10 mg/kg vs 8.2% with 10 mg/kg). Furthermore, the tumor type was not significantly associated with the incidence of hypothyroidism with PD-1 inhibitors. Moreover, when we restricted the analysis to the subset of trials that included only patients with melanoma, the differences between combination therapy and monotherapy with CTLA-4 or PD-1 inhibitors were of similar magnitude and remained statistically significant.
Incidence of Hyperthyroidism
The incidence of hyperthyroidism for all grades and for grade 3 and higher in 37 studies is described in eTable 1 in the Supplement. One study did not report events; across all other study cohorts, 194 cases of any-grade hyperthyroidism were observed among the 7531 patients. Only 7 cases of grade 3 or higher hyperthyroidism (0.10%) were reported.
Based on the mixed-effects model, the overall incidence of hyperthyroidism was estimated to be 2.9% (95% CI, 2.4%-3.7%), and a statistically significant difference was observed among the classes of immunotherapy (P < .001) ( Figure 3 ). 14, 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] The predicted incidence in hyperthyroidism ranged from 0.6% (95% CI, 0.2%-1.8%) with the PD-L1 inhibitor to 8.0% (95% CI, 4.1%-15.3%) with combination therapy. Patients treated with the combination regimen were significantly more likely to experience any grade hyperthyroidism than those treated with ipilimumab monotherapy (OR, 4.27; 95% CI, 2.05-8.90; P = .001) (eTable 2 in the Supplement); whereas increased incidence in patients who received PD-1 inhibitors failed to reach statistical significance after correcting for multiple comparisons (OR, 1.89; 95% CI, 1.02-3.52; adjusted P = .13). The risk of hyperthyroidism was significantly greater with PD-1 inhibitors than with PD-L1 inhibitors (OR, 5.36; 95% CI, 2.04-14.08; adjusted P = .002). The odds of experiencing hyperthyroidism were not significantly different between patients treated with PD-L1 inhibitors and ipilimumab. The test of residual heterogeneity among studies was not significant (Q = 61, P = .62, I 2 = 18.3%) (eFigure 1 in the Supplement).
Regarding the PD-1 inhibitors, there was a significant difference in rates of hyperthyroidism observed between nivolumab and pembrolizumab (respectively, 2.5% [95% CI, 1.3%-4.6%] vs 3.8% [95% CI, 2.1%-6.9%], P = .04), but no significant difference between low-and high-dose pembrolizumab that could account for the difference between the 2 agents was noted. Furthermore, tumor type was not significantly associated with the incidence of hyperthyroidism with PD-1 inhibitors. The difference in hyperthyroidism incidence among classes of ICI remained statistically significant within the subset of melanoma trials.
Incidence of Hypophysitis
The incidence of hypophysitis for all grades and for grade 3 and higher in the 34 studies that reported this toxic effect is described in eTable 1 in the Supplement. A total of 85 cases of any grade hypophysitis were observed among 6472 patients. Among these cases, 76 occurred in patients with melanoma. A total of 34 cases of grade 3 or higher hypophysitis were reported (0.5%). Overall, the observed incidence of hypophysitis was greatest with combination therapy at 6.4%; 3.2%, CTLA-4 inhibitors; 0.4%, PD-1 inhibitors; and less than 0.1%, PD-L1 inhibitors (eFigure 2 in the Supplement). Due to the low incidence in other diseases (9 of 3394 cases treated [0.3%]), meta-analysis models of drug-specific effects were restricted to studies in advanced melanoma that reported the incidence of hypophysitis (76 of 3078 cases treated [2.5%]) ( Figure 4) . 18 
Incidence of Primary Adrenal Insufficiency and Insulin Deficient Diabetes
The incidence of all grade PAI and IDD following the use of ICI is described in eTable 1 in the Supplement. For these AEs, no statistical inferences were made due to the smaller number of events. Four studies did not report events; across the other 62 study cohorts, 43 cases of any-grade PAI were reported among 5831 patients (0.7%), 14 of which (0.2%) were graded 3 or higher. Importantly, among the 262 patients who received combination therapy and had data on adrenal insufficiency reported, 11 experienced PAI, reflecting a reported incidence of 4.2% in this group. Regarding IDD, only 13 cases of any-grade were reported (0.2%), with 6 cases indicated as grade 3 or higher (0.1%). Notably, all but 1 case was observed in patients treated with PD-1 inhibitors.
Discussion
This meta-analysis shows that the incidence of different endocrine AEs following ICIs is significantly higher in patients on combination therapy compared with patients treated with monotherapy. Among patients on monotherapy regimens, the incidence of thyroid dysfunction was higher in those treated with anti-PD-1 agents; conversely, the incidence of hypophysitis was highest in those treated with ipilimumab. Furthermore, there was no association between the tumor type and the incidence of ICI-induced thyroid dysfunctions. To our knowledge, this is the most comprehensive systematic review and meta-analysis on the incidence of endocrine dysfunction following the use of FDA-approved ICI regimens in patients with advanced solid tumors. Although a previous meta-analysis showed that, overall, ICIs are associated with increased risk of hypothyroidism or hyperthyroidism, hypophysitis, and adrenal insufficiency compared with placebo or chemotherapy, 51 our study is the first that we know of to compare the incidence and risks of such irAEs associated with each different regimen, and the first that we know of to also include trials with PD-L1 inhibitors or combination therapy. Garon et al, 24 2015
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10,51,52 Notably, ICI may rarely induce life-threatening thyroid storm. 53 In our data set, there were rare grade 3 hypothyroidism and hyperthyroidism events (0.2%). Our study demonstrated a higher incidence of hypothyroidism among patients who received combination therapy or PD-1 inhibitors compared with those who received ipilimumab. There was no statistically significant difference in the risk of hypothyroidism between PD-L1 inhibitors and PD-1 inhibitors, or between PD-L1 inhibitors and ipilimumab. Multivariable analysis also showed no relationship between hypothyroidism and tumor type, type of PD-1 inhibitor, or dose of pembrolizumab. Furthermore, compared with those on ipilimumab, patients on combination therapy were more likely to develop hyperthyroidism, whereas increased incidence in patients who received PD-1 inhibitors failed to reach statistical significance in the adjusted analysis. Additionally, there was a higher incidence of hyperthyroidism among patients receiving PD-1 inhibitors compared with those receiving PD-L1 inhibitors, and among those treated with pembrolizumab compared with nivolumab. A precise explanation for these observed differences is unknown. However, based on prior clinical studies, 52,54 and rarity of Graves disease following the use of ICIs, 55,56 we can hypothesize that, in most cases, both hypothyroidism and hyperthyroidism following the use of these agents are different manifestations of the same pathological entity: a destructive thyroiditis mediated by cytotoxic T cells against the thyroid gland. Thus, a possible explanation for the observed differences across ICI regimens may be the fact that monotherapy may be associated with a milder and more transient thyrotoxicosis phase, making it possible to miss in nonscheduled thyroid function tests. Moreover, it is also unclear why there are higher rates of thyroid dysfunction in patients on PD-1 inhibitors compared with those on PD-L1 inhibitors or on ipilimumab. One hypothesis for this is that there is a role for PD-L2 (programmed cell death 1 ligand 2) blockade in the pathogenesis of thyroid dysfunction, as there is now data that normal thyroid tissue expresses both PD-L1 and PD-L2 molecules. 57 Unfortunately, none of the 38 studies included in this analysis specify the etiology of hyperthyroidism. Hypophysitis has emerged as the most common endocrine dysfunction induced during ipilimumab therapy, 9, 58, 59 and, if unrecognized, can be life threatening. In our study, given the low incidence of hypophysitis in patients with nonmelanoma tumors, we restricted our analysis to include only studies of melanoma. In this subset, the incidence of hypophysitis was statistically higher among patients on combination therapy, followed by those on ipilimumab alone, and rarely reported among patients treated with PD-1 inhibitors alone.
Although the pathogenesis of hypophysitis secondary to CTLA-4 blockade remains unknown, previous studies 60, 61 suggest an autoimmune-based mechanism. Iwama et al 60 showed that CTLA-4 protein is expressed in murine and human pituitary glands, and that repeated injections of an anti-CTLA-4 monoclonal antibody induce a mouse model of Wolchok et al, 36 2013 Larkin et al, 19 2015 Robert et al, 32 2014 Robert et al, 18 2015 Ribas et al, 23 compared the efficacy and safety of ipilimumab 10 mg/kg or 3 mg/kg (every 3 weeks for 4 doses) in patients with advanced melanoma. Although the higher dose improved overall survival of patients, it was also associated with increased rates of any-grade irAEs compared with the lower dose, as well as hypophysitis (6.6% vs 3.3%), hypothyroidism (2.2% vs 1.9%) and thyroiditis (1.4% vs 0.6%).
Less is known about ICI-induced PAI and IDD. Although our study found only 43 cases of any grade PAI reported among 5831 patients (0.7%), the reported rate of PAI among patients on combination therapy was 4.2%. Likewise, among the 13 cases of any-grade IDD reported, 12 occurred on anti-PD-1 therapy and 1 on ipilimumab. For these AEs, no statistical inferences were made due to the small number of events. To date, few case reports have been published on these types of irAEs.
Limitations
Our study has several limitations. We conducted our metaanalysis at the study level; therefore, variables at the patient level were not available for this analysis. Thus, we could not establish additional potential risk factors possibly associated with the development of endocrine AEs, including the role of sex, baseline thyroid or pituitary functions, or presence of thyroid autoantibodies. In addition, the use of metaanalytic techniques to pool published summary data are associated with the possibility of missing studies, heterogeneity of included studies, and the use of aggregated patient data, which can restrict the ability to check for uniform definitions of outcome variables. Importantly, the studies included in this analysis had different rules to monitor patients for endocrine dysfunctions, which could have influenced the reported incidence of these AEs across these various protocols.
Conclusions
Our study provides more precise data on the incidence of endocrine irAEs induced by different ICI regimens. Although combination therapy with ICIs has strong preclinical rationale and showed an improvement in progressionfree survival in patients with melanoma, this approach increases the risk of endocrine dysfunction following its use. While all 4 drugs included in our study block immune checkpoint molecules, the differences in the incidence of the above discussed endocrine AEs suggest that the CTLA-4 and PD-1 or PD-L1 or PD-L2 axes have distinct importance in the maintenance of immune tolerance against the thyroid, pituitary, and adrenal glands. Based on our results, we do recommend monitoring of thyroid-stimulating hormone and free thyroxine levels before each ICI infusion for at least the first 5 cycles of therapy. Concur rent Study-level data are displayed as box-and-whiskers using binomial exact 95% confidence intervals.
